Calprotectin and Calgranulin C as Biomarkers of Pancreatic Tumors: Baseline Levels and Level Changes after Surgery

Table 1

Demographic and clinical data of the study group.

Patients
Age in years (mean)	61.4
Gender (male/female)	56/57
Conditions		%	Age	M/F
Ductal adenocarcinoma	60	53.1	64.4	26/34
Neuroendocrine tumor	16	14.2	58	9/7
Benign tumor	14	12.4	50.9	7/7
Intraductal papillary mucinous neoplasm	6	5.3	63.8	4/2
Mucinous cystadenocarcinoma	5	4.4	55.8	1/4
Distal bile duct carcinoma	6	5.3	66.6	5/1
Ampulla of Vater carcinoma	4	3.5	62.5	2/2
Inconclusive histology	1	0.9	62.1	1/0
Another tumor type	1	0.9	64	1/0
Operations
Pancreatoduodenectomy	64	56.6	61.9	32/32
Distal pancreatectomy	28	24.8	62.1	12/16
Palliative procedures	8	7.1	61	5/3
Total pancreatectomy	9	8.0	57.6	5/4
Other	4	3.5	58	2/2
Complications
None	61	54.0	59.4	29/32
Complication grade A	11	9.7	65.3	7/4
Complication grade B	12	10.6	65.2	5/7
Complication grade C	14	12.4	62.1	10/4
Other	15	13.3	63	5/10